Hello, everyone, and welcome to another busy day. This is the middle of the week, after all. As for us, we are quaffing cups of stimulation to stay focused as we bid adieu to two of our short people, who are returning to their busy lives elsewhere after an enjoyable holiday break here at the Pharmalot campus. We will miss them. Now, though, time to get cracking. Here is the usual slew of tidbits. Have a great day and keep in touch …
Valeant Pharmaceuticals plans to appoint a new chief executive while Michael Pearson remains hospitalized, The Wall Street Journal reports. For the moment, it is not clear whether the change would be permanent or temporary. The possible candidates who may replace Pearson include Howard Schiller, a Valeant director who resigned as chief financial officer last year, and Robert Rosiello, who replaced him.
Editas Medicine filed documents to sell stock publicly for the first time, underscoring the fascination with the CRISPR gene-editing technique, but the move also cast a spotlight on a simmering patent battle, STAT tells us. Expect to see “some heated litigation,” said Jacob Sherkow of New York Law School. The stock sale is also likely to raise prematurely raise patient hopes for new cures as CRISPR advances are reported from labs.
About the Author Reprints
